Header Logo

Connection

Frederick Raal to Atherosclerosis

This is a "connection" page, showing publications Frederick Raal has written about Atherosclerosis.
Connection Strength

7,493
  1. Heart groups in South Africa advocate for tighter LDL-C control and lipoprotein(a) testing to curb atherosclerotic cardiovascular disease. S Afr Med J. 2024 May 09; 114(5):e1973.
    View in: PubMed
    Score: 0,831
  2. Dyslipidaemia in patients with chronic kidney disease - a neglected cardiovascular risk factor. S Afr Med J. 2023 Nov 06; 113(11):35-40.
    View in: PubMed
    Score: 0,803
  3. ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis. Curr Atheroscler Rep. 2022 12; 24(12):959-967.
    View in: PubMed
    Score: 0,750
  4. Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: A subanalysis of the ORION phase III clinical trials. S Afr Med J. 2022 05 31; 112(6):426-432.
    View in: PubMed
    Score: 0,727
  5. RNA-based therapy in the management of lipid disorders: a review. Lipids Health Dis. 2022 Apr 23; 21(1):41.
    View in: PubMed
    Score: 0,721
  6. Management of familial hypercholesterolemia in pregnancy. Curr Opin Lipidol. 2021 12 01; 32(6):370-377.
    View in: PubMed
    Score: 0,702
  7. Novel therapies for familial hypercholesterolemia. Curr Opin Endocrinol Diabetes Obes. 2021 04 01; 28(2):188-195.
    View in: PubMed
    Score: 0,670
  8. Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease. Cardiovasc Drugs Ther. 2016 Feb; 30(1):101-8.
    View in: PubMed
    Score: 0,469
  9. Sex Differences in Diagnosis, Treatment, and Cardiovascular Outcomes in Homozygous Familial Hypercholesterolemia. JAMA Cardiol. 2024 Apr 01; 9(4):313-322.
    View in: PubMed
    Score: 0,206
  10. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023 Jul 01; 44(25):2277-2291.
    View in: PubMed
    Score: 0,196
  11. International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia. Nat Rev Cardiol. 2023 12; 20(12):845-869.
    View in: PubMed
    Score: 0,195
  12. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 2022 12 21; 43(48):5047-5057.
    View in: PubMed
    Score: 0,189
  13. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. J Am Coll Cardiol. 2021 03 09; 77(9):1182-1193.
    View in: PubMed
    Score: 0,167
  14. Poor cardiovascular health is associated with subclinical atherosclerosis in apparently healthy sub-Saharan African populations: an H3Africa AWI-Gen study. BMC Med. 2021 02 10; 19(1):30.
    View in: PubMed
    Score: 0,166
  15. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020 06 21; 41(24):2313-2330.
    View in: PubMed
    Score: 0,159
  16. PCSK9 Inhibitors: From Nature's Lessons to Clinical Utility. Endocr Metab Immune Disord Drug Targets. 2020; 20(6):840-854.
    View in: PubMed
    Score: 0,154
  17. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017 Aug 21; 38(32):2459-2472.
    View in: PubMed
    Score: 0,130
  18. Adiponectin and atherosclerosis risk factors in African hemodialysis patients: a population at low risk for atherosclerotic cardiovascular disease. Hemodial Int. 2012 Jan; 16(1):59-68.
    View in: PubMed
    Score: 0,088
  19. Drugs for dyslipidaemia: the legacy effect of the Scandinavian Simvastatin Survival Study (4S). Lancet. 2024 Dec 14; 404(10470):2462-2475.
    View in: PubMed
    Score: 0,054
  20. Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. Lancet Diabetes Endocrinol. 2020 01; 8(1):50-67.
    View in: PubMed
    Score: 0,038
  21. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015 Sep 21; 36(36):2425-37.
    View in: PubMed
    Score: 0,028
  22. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014 Aug 21; 35(32):2146-57.
    View in: PubMed
    Score: 0,026
  23. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013 Dec; 34(45):3478-90a.
    View in: PubMed
    Score: 0,025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.